Robert N. Davidson, L. D. Martino, L. Gradoni, Raffaella Giacchino, R. Russo, Giovanni Battista Gaeta, R. Pempinello, S. Scott, Francesco Raimondi, Antonio Cascio, Tullio Prestileo, L. Caldeira, Robert J. Wilkinson, A. Bryceson
{"title":"脂质体两性霉素B (AmBisome)在地中海内脏利什曼病:一项多中心试验。","authors":"Robert N. Davidson, L. D. Martino, L. Gradoni, Raffaella Giacchino, R. Russo, Giovanni Battista Gaeta, R. Pempinello, S. Scott, Francesco Raimondi, Antonio Cascio, Tullio Prestileo, L. Caldeira, Robert J. Wilkinson, A. Bryceson","doi":"10.1093/OXFORDJOURNALS.QJMED.A068903","DOIUrl":null,"url":null,"abstract":"Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.","PeriodicalId":54520,"journal":{"name":"Quarterly Journal of Medicine","volume":"87 2 1","pages":"75-81"},"PeriodicalIF":0.0000,"publicationDate":"1994-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/OXFORDJOURNALS.QJMED.A068903","citationCount":"188","resultStr":"{\"title\":\"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.\",\"authors\":\"Robert N. Davidson, L. D. Martino, L. Gradoni, Raffaella Giacchino, R. Russo, Giovanni Battista Gaeta, R. Pempinello, S. Scott, Francesco Raimondi, Antonio Cascio, Tullio Prestileo, L. Caldeira, Robert J. Wilkinson, A. Bryceson\",\"doi\":\"10.1093/OXFORDJOURNALS.QJMED.A068903\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.\",\"PeriodicalId\":54520,\"journal\":{\"name\":\"Quarterly Journal of Medicine\",\"volume\":\"87 2 1\",\"pages\":\"75-81\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/OXFORDJOURNALS.QJMED.A068903\",\"citationCount\":\"188\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Quarterly Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/OXFORDJOURNALS.QJMED.A068903\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quarterly Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/OXFORDJOURNALS.QJMED.A068903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
